MTHFR C677T基因多态性与脑小血管病认知功能障碍的相关性研究

doi:10.3969/j.issn.1673-5765.2019.11.004

摘要/Abstract

摘要：

目的探讨MTHFR C677T基因多态性与脑小血管病（cerebral small vessel disease，CSVD）患者认知功能障碍的相关性。方法选取2017年12月-2019年3月在潍坊市人民医院神经内科就诊的门诊及住院CSVD患者，参照蒙特利尔认知评估量表（Montreal cognitive assessment，MoCA）和临床痴呆评定量表评分，将患者分为 3组：认知功能正常组，轻度认识功能障碍组和痴呆组。所有患者均取晨起空腹静脉血测定Hcy水平及MTHFR C677T基因型，分析Hcy水平、MTHFR C677T基因型与CVSD患者认知功能障碍的相关性。结果共纳入130例CSVD患者，其中男性87例（66.9%）。认知功能正常组63例，轻度认识功能障碍组35例，痴呆组32例。痴呆组患者血清Hcy水平高于轻度认知功能障碍组（P＜0.001）和认知功能正常组（P＜0.001），轻度认知功能障碍组血清Hcy水平高于认知功能正常组（P＜0.001）。Hcy水平与 CSVD患者认知功能下降程度正相关（r =0.626，P＜0.001）。MTHFR 677 C→T基因突变与CSVD患者认知功能下降程度正相关（r =0.359，P =0.001）。T等位基因频率与CSVD患者认知功能障碍弱正相关（r =0.273，P＜0.001）。结论 MTHFR 677 C→T基因突变与CSVD患者认知功能障碍的发生及进展正相关，可作为早期预测认知功能障碍的血清学标志物之一。

文章导读： 本研究对CSVD患者MTHFR C677T基因多态性与认知功能损害及其损害程度进行相关分析，发现MTHFR的T等位基因可能是CSVD患者认知功能障碍的危险因素，且其突变率与认知功能损害程度正相关，提示MTHFR基因型检查可能是CSVD认知障碍早期筛查的生物标志物之一。

关键词: 脑小血管病；5; 10-亚甲基四氢叶酸还原酶；同型半胱氨酸；认知功能

Abstract:

Objective To investigate the correlation between MTHFR C677T gene polymorphism and cognitive impairment in patients with cerebral small vessel disease (CSVD). Methods This was a retrospective study which included the CSVD outpatients and inpatients in Department of Neurology,Weifang People's Hospital between December 2017 to March 2019. Based on the Montreal cognitive assessment (MoCA) and clinical dementia rating (CDR) score, the patients were divided into three groups: normal cognition group, mild cognitive impairment group and dementia group. The level of homocysteine (Hcy), and MTHFR C677T phenotype were measured. The relationship between cognitive function and Hcy or MTHFR C677T phenotype were analyzed by comparing the above data among three groups. Results A total of 130 CSVD patients were enrolled into this study, including 87 males (66.9%), and with 63 patients in normal cognition group, 35 patients in mild cognitive impairment group and 32 patients in dementia group. The Hcy level in dementia group was significantly higher than that in mild cognitive impairment group (P <0.001) and normal cognition group (P <0.001). The Hcy level in mild cognitive impairment group was significantly higher than that in normal cognition group (P <0.001).The level of Hcy was positively correlated with cognitive decline (r =0.626, P <0.001). The frequency of C677T MTHFR mutation (C→T) genotype was positively correlated with cognitive decline (r =0.359, P =0.001). The frequency of T allele was positively correlated with cognitive decline (r =0.273, P <0.001). Conclusions MTHFR 677 C→T gene mutation was associated with cognitive decline, and it can be used as an early serum predictor for cognitive impairment in CSVD.

Key words: Cerebral small vessel disease; 5,10-methylenetetrahydrofolate reductase;Homocysteine; Cognitive function

汪明玉, 张立辉, 周浩, 赵勇. MTHFR C677T基因多态性与脑小血管病认知功能障碍的相关性研究[J]. 中国卒中杂志, 2019, 14(11): 1095-1100.

WANG Ming-Yu, ZHANG Li-Hui, ZHOU Hao, ZHAO Yong. Correlation between MTHFR C677T Gene Polymorphism and Cognitive Impairment in Patients with Cerebral Small Vessel Disease[J]. Chinese Journal of Stroke, 2019, 14(11): 1095-1100.

参考文献

[1] KALARIA R N. The Pathology and Pathophysiology

of Vascular Dementia [J]. Neuropharmacology，2018，

134（1）：226-239.

[2] LIU Y，DONG Y H，LYU P Y，et al. Hypertensioninduced

cerebral small vessel disease leading to

cognitive impairment [J]. Chin Med J（Engl），2018，

131（5）：615-619.

[3] CHEN X，WANG J，SHAN Y，et al. Cerebral small

vessel disease：neuroimaging markers and clinical

implication[J]. J Neuro，266（10）：2347-2362.

[4] RUTTEN-JACOBS L C，TRAYLOR M，ADIBSAMII

P，et al. Association of MTHFR C677T

genotype with ischemic stroke is confined to cerebral

small vessel disease subtype[J]. Stroke，2016，47（3）：

646-651.

[5] SZOLNOKI Z，SZANISZLO I，SZEKERES M，et

al. Evaluation of the MTHFR A1298C variant in

leukoaraiosis[J]. J Mol Neurosci，2012，46（3）：492-

496.

[6] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国脑小血管病诊治共识[J]. 中华

神经科杂志，2015，48（10）：838-844.

[7] LIAKAKIS G. Biochemical diagnosis of vascular

cognitive impairment associated with subcortical

small vessel disease[J]. Hell J Nucl Med，2019，22

（1-4）：187-193.

[8] WARDLAW J M，SMITH C，DICHGANS M，et al.

Mechanisms of sporadic cerebral small vessel disease：

insights from neuroimaging[J]. Lancet Neurol，2013，

12（5）：483-497.

[9] PANTONI L. Cerebral small vessel disease：from

pathogenesis and clinical characteristics to

therapeutic challenges[J]. Lancet Neurol，2010，9

（7）：689-701.

[10] JACKSON C A，HUTCHISON A，DENNIS M

S，et al. Differing risk factor profiles of ischemic

stroke subtypes：evidence for a distinct lacunar

arteriopathy?[J]. Stroke，2010，41（4）：624-629.

[11] MA Y，ZHAO X，ZHANG W，et al. Homocysteine

and ischemic stroke subtype：a relationship study in

Chinese patients[J]. Neurol Res，2010，32（6）：636-

641.

[12] LIU J，JIN X，LIU K J，et al. Matrix

metalloproteinase-2mediated occludin degradation

and caveolin-1-mediated claudin-5 redistribution

contribute to blood-brain barrier damage in early

ischemic stroke stage[J]. J Neurosci，2012，32（9）：

3044-3057.

[13] TIAN X，ZHAO L，SONG X，et al. HSP27 inhibits

homocysteine-induced endothelial apoptosis by

modulation of ROS production and mitochondrial

caspase-dependent apoptotic pathway[J/OL].

Biomed Res Intl，2016：4847874. https：//doi.org/10.

1155/2016/4847874.

[14] LAI W K，KAN M Y. Homocysteine-induced

endothelial dysfunction[J]. Ann Nutr Metab，2015，

67（1）：1-12.

[15] BIESBROEK J M，WEAVER N A，BIESSELS G

J. Lesion location and cognitive impact of cerebral

small vessel disease[J]. Clin Sci（Lond），2017，131

（8）：715-728.

[16] LU D，LI P，ZHOU Y，et al. Association between

serum non-highdensity lipoprotein cholesterol and

cognitive impairment in patients with acute ischemic

stroke[J]. BMC Neurol，2016，16（1）：154-163.

[17] DUFOUIL C，ALPÉROVITCH A，DUCROS V，et

al. Homocysteine，white matter hyperintensities，

and cognition in healthy elderly people[J]. Ann

Neurol，2003，53（2）：214-221.

[18] VAN DEN KOMMER T N，DIK M G，COMIJS H

C，et al. Homocysteine and inflammation：predictors

of cognitive decline in older persons?[J]. Neurobiol

Aging，2010，31（10）：1700-1709.

[19] SHANKLE W R，HARA J，BARRENTINE L W，et

al. CerefolinNAC therapy of hyperhomocysteinemia

delays cortical and white matter atrophy in

Alzheimer's disease and cerebrovascular disease[J]. J

Alzheimers Dis，2016，54（3）：1073-1084.

[20] MOORE E，MANDER A，AMES D，et al.

Cognitive impairment and vitamin B12：a review[J].

Int Psychogeriatr，2012，24（4）：541-556.

[21] LIEW S C，GUPTA E D. Methylenetetrahydrofolate

reductase（MTHFR）C677T polymorphism：

epidemiology，metabolism and theassociated

diseases[J]. Eur J Med Genet，2015，58（1）：1-10.

[22] LI A，SHI Y，XU L，et al. A possible synergistic

effect of MTHFR C677T polymorphism on

homocysteine level variations increased risk for

ischemic stroke[J]. Medicine，2017，96（51）：51-56.

[23] CHOI B O，KIM N K，KIM S H，et al. Homozygous

C677T mutation in the MTHFR gene as an

independent risk factor for multiple small-artery

occlusions[J]. Thromb Res，2003，11（1-2）：39-44.